Clinical trial AMG510 20190009 - CodeBreak 200
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled, Study of AMG 510 versus Docetaxel for the treatment of Previously treated locally Advanced and unresectable or Metastatic NSCLC Subjects with mutated KRAS p.G12C
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Amgen |
| EudraCT Identifier | 2019-003582-18 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04303780 |
| Inclusion criteria | NSCLC |
| Last update |